Novartis Ag

Dominik Feuerbach

Konstanze Hurth

Bernard Lucien Roy

Mathias Frederiksen

Timothy John Ritchie

Donald Johns

Baltazar Gomez-Mancilla

Manuel Koller

Markus Weiss

Thomas Josef Troxler

Joachim Nozulak

Kevin Hall McAllister

Cristina Lopez-Lopez

Beatrix Wagner

Yunsheng He

Werner Müller

Lisa Sandford

Rochdi Bouhelal

Nicole Pezous

Fabrizio Gasparini

Eveline Schaadt

Markus Waldhuber

Christer Halldin

Nathalie George

Rainer Wilcken

Judit Sovago

Thérèse Di Paolo

Derya Shimshek

Sjoerd Johannes Finnema

Martin Marzi

Verena Brand

Honnappa Srinivas

Markus Fendt

The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

TREM2 stabilizing antibodies

The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.

Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.

Use of alpha 7 nicotinic acetylcholine receptor agonists

The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Use of nicotinic acetylcholine receptor alpha 7 activators

The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CHor a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists

The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acetylcholine receptors (NACHR) ligands. 

Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators

Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists

The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C-C, substituted or unsubstituted hetero-C-Caryl, a group N(R)(R), or a group N(R)(CHPR); R represent a hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents a substituted or unsubstituted C-Caryl or a substituted or unsubstituted C-Cheteroaryl; in free base or acid addition salt form. 

1-aza-bicyclo[3.3.1]nonanes

The present invention related to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: (Ia) in free base or acid addition salt form, to processes for their production, to pharmaceutical compositions comprising them and their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and neurodegenerative disorders. 

1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders

Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists

The present invention relates to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: (Ia) in free base or acid addition salt form, to processes for their production, to pharmaceutical compositions comprising them and their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and neurodegenerative disorders. 

Organic compounds

The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and nemodegenerative disorders. 

Growing community of inventors

Müllheim, Germany

Dominik Feuerbach